Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279293 | 0.94 | PPARG (0.43) | PPARGBRAFMAPK1TRPV1PTGER4 | |
| SCHEMBL9939578 | 0.93 | CNR2 (0.41) | PPARGBRAFMAPK1HDAC3HDAC1 | |
| SCHEMBL9939575 | 0.93 | TRPV1 (0.42) | PPARGMAPK1TRPV1PTGER4MAOB | |
| SCHEMBL9939182 | 0.92 | MAOB (0.40) | PPARGMAPK1HDAC1MAOBMAPK10 | |
| SCHEMBL9939464 | 0.90 | PPARG (0.43) | PPARGMAPK1TRPV1MAOBMAPK10 | |
| SCHEMBL9900564 | 0.89 | TP53 (0.40) | BRAFMAPK1HDAC3HDAC1HDAC2 | |
| SCHEMBL9900567 | 0.89 | TP53 (0.40) | BRAFMAPK1HDAC3HDAC1HDAC2 | |
| SCHEMBL9938507 | 0.87 | TRPV1 (0.37) | PPARGTRPV1PTGER4MAOB | |
| SCHEMBL9939568 | 0.87 | PPARG (0.40) | PPARGBRAFMAPK1TRPV1PTGER4 | |
| SCHEMBL9939489 | 0.87 | SMN1; SMN2 (0.39) | CNR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2648710-B1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140051727-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012078869-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | PPARG 1784/4885BRAF 1620/4885MAPK1 1978/4885 |
| US-20140051727-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | PPARG 1784/4885BRAF 1620/4885MAPK1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.